Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | CTSC | P53634 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665238 | 0.97 | REN (0.53) | RENSRCCTSCACEMME | |
| SCHEMBL30051269 | 0.89 | REN (0.60) | RENCTSCACEMMECPA1 | |
| SCHEMBL31688178 | 0.89 | REN (0.51) | RENSRCACEMMECPA1 | |
| SCHEMBL31688170 | 0.89 | REN (0.51) | RENSRCACEMMECPA1 | |
| SCHEMBL31104091 | 0.88 | REN (0.58) | RENNTSR2NTSR1SORT1 | |
| SCHEMBL29357733 | 0.87 | REN (0.57) | RENNTSR2NTSR1CTSKSORT1 | |
| Hydrochloric Acid SCHEMBL8614633 | 0.85 | REN (0.55) | RENSRCCTSC | |
| Hydrochloric Acid SCHEMBL8614647 | 0.85 | REN (0.55) | RENSRCCTSC | |
| SCHEMBL27204707 | 0.85 | REN (0.50) | RENSRCACEMMECPA1 | |
| SCHEMBL27172513 | 0.85 | REN (0.50) | RENSRCACEMMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-01 | — | — | US | disclosed |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | OHIO STATE INNOVATION FOUNDATION | 2024-10-31 | — | — | US | disclosed |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-11878046-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-09-29 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11351222-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220160819-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | VIP, LNPEP, IAPP | REN 3039/4885SRC 3804/4885CTSC 419/4885 |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | SLC3A2, SPPL2B, SLC7A1 | REN 3017/4885SRC 2693/4885CTSC 210/4885 |
| US-11878046-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | IKBKE, IKBKB, SHARPIN | REN 4648/4885SRC 1595/4885CTSC 2103/4885 |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | REN 3750/4885SRC 2862/4885CTSC 84/4885 |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | REN 3750/4885SRC 2862/4885CTSC 84/4885 |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC38A7, SLC7A1, SLC6A7 | REN 1257/4885SRC 1466/4885CTSC 337/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | REN 1662/4885SRC 2226/4885CTSC 891/4885 |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | CHN2, TAP2, VIP | REN 2618/4885SRC 4043/4885CTSC 401/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | REN 4125/4885SRC 881/4885CTSC 364/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | REN 3405/4885SRC 3306/4885CTSC 85/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | REN 2030/4885SRC 1049/4885CTSC 786/4885 |
| US-20220160819-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | IKBKE, IKBKB, SHARPIN | REN 4648/4885SRC 1595/4885CTSC 2103/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | REN 2481/4885SRC 1034/4885CTSC 930/4885 |
| US-11351222-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | IKBKE, IKBKB, SHARPIN | REN 4648/4885SRC 1595/4885CTSC 2103/4885 |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | REN 2364/4885SRC 920/4885CTSC 759/4885 |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | CHN2, TAP2, VIP | REN 2618/4885SRC 4043/4885CTSC 401/4885 |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | REN 1284/4885SRC 1177/4885CTSC 363/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | REN 4059/4885SRC 3235/4885CTSC 335/4885 |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | VIP, LNPEP, NGLY1 | REN 3492/4885SRC 4351/4885CTSC 59/4885 |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | VIP, LNPEP, TAP1 | REN 4229/4885SRC 3461/4885CTSC 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.